97 Results for "

Hep3B

" in MedChemExpress (MCE) Product Catalog:
Products (97)

97 Results for "Hep3B" in MCE Product Catalog:

96
96 Publications Verification
Cat. No.: HY-10331
CAS No.: 755037-03-7
Purity:  99.93%
Synonyms: BAY 73-4506
Research Areas:  

Cancer

Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .
loading...
    loading...
96
96 Publications Verification
Cat. No.: HY-10331A
CAS No.: 1019206-88-2
Purity:  99.96%
Synonyms: BAY 73-4506 monohydrate
Research Areas:  

Cancer

Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-101568
CAS No.: 1708971-55-4
Purity:  99.67%
Synonyms: FGF-401
Target:  

FGFR

Research Areas:  

Cancer

Roblitinib (FGF-401) is an orally active and highly selective FGFR4 inhibitor with an IC50 of 1.9 nM . Roblitinib has antitumor activity .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-101513
CAS No.: 2095486-67-0
Purity:  99.96%
eIF4A3-IN-1 is a selective eIF4A3 inhibitor (IC50: 0.26 μM; Kd: 0.043 μM) with cellular nonsense-mediated RNA decay (NMD) inhibitory activity. eIF4A3-IN-1 can specifically bind to the non-ATP binding site of eIF4A3. eIF4A3-IN-1 has anti-tumor and analgesic activities [3].
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-N0699
CAS No.: 2034-69-7
Synonyms: Dephnoretin; Thymelol
Daphnoretin (Dephnoretin; Thymelol) is a protein kinase C (PKC) activator that inhibits the expression of hepatitis B virus (HBV) surface antigen (HBsAg) and exhibits antiviral activity. Daphnoretin exerts its antitumor effects by inhibiting the activation of the PI3K/AKT signaling pathway and triggers the mitochondrial apoptosis pathway. Daphnoretin alleviates chondrocyte apoptosis and inflammatory responses by inhibiting endoplasmic reticulum stress and activation of the NLRP3 inflammasome. Daphnoretin regulates the differentiation and maturation of dendritic cells, inhibits their immunostimulatory function by downregulating the phosphorylation level of JNK, and thus exerts a protective effect in skin graft rejection [3] .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-N2445
CAS No.: 37308-75-1
Flavokawain C is an orally active natural chalcone. Flavokawain C inhibits the proliferation of various cancer cells. Flavokawain C upregulates GADD153 in cancer cells, inhibits the phosphorylation of Akt and JNK, suppresses early ERK phosphorylation, activates late ERK phosphorylation, activates caspase related subtypes, induces PARP-1 cleavage, causes upregulation of p21 and p27, downregulation of mutant p53 and anti-apoptotic IAP proteins, elevates intracellular ROS levels, reduces SOD activity, and induces apoptosis. Flavokawain C downregulates FABP4, induces autophagy in cancer cells, and activates the AMPK/mTOR pathway . Flavokawain C decreases the expression of glycolysis-related proteins GLUT1 and HK2, and inhibits glycolysis in nasopharyngeal carcinoma cells. Flavokawain C inhibits the activation of the EGFR/PI3K/Akt/mTOR signaling pathway and reduces the expression of HSP90B1. Flavokawain C inhibits angiogenesis by decreasing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells. Flavokawain C increases γ-H2AX levels in cells, inhibits the phosphorylation of FAK, PI3K and AKT in cells, and induces DNA damage in cells. Flavokawain C exerts anti-tumor activity in multiple tumor xenograft mouse models. Flavokawain C is applicable to research related to colorectal cancer, colon adenocarcinoma, nephroblastoma, nasopharyngeal carcinoma and liver cancer [3] .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-N0316
CAS No.: 55481-88-4
Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway [3].
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-153967
CAS No.: 2810747-78-3
Purity:  95.92%
Target:  

PKA

Research Areas:  

Cancer

BLU0588 is an orally active, potent and selective PRKACA (protein kinase cAMP-activated catalytic subunit alpha) kinase inhibitor, with an IC50 of 1 nM and dissociation constant (Kd) of 4 nM. BLU0588 can be used for fibrolamellar carcinoma (FLC) research .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-N2322
CAS No.: 32449-98-2
Khasianine is a steroidal glycoalkaloid . Khasianine alleviates psoriasis-like skin inflammation by inhibiting the TNF-α/NF-κB axis. Khasianine can downregulate the RhoA pathway and exhibits potential antimetastatic activity. Khasianine upregulates the expression of TNFR I and TNFR II without inducing apoptotic effects . Khasianine can be used in studies related to psoriasis, pancreatic ductal adenocarcinoma, and liver cancer [3].
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-139287
CAS No.: 823830-85-9
Purity:  99.69%
Research Areas:  

Cancer

M1002 is a hypoxia-inducible factor-2 (HIF-2) agonist, and can enhance the expression of HIF-2 target genes. M1002 shows synergy with prolyl-hydroxylase domain (PHD) inhibitors .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-115449
CAS No.: 331859-86-0
Purity:  99.80%
Synonyms: 94G6
Target:  

IGF-1R Akt mTOR

Research Areas:  

Cancer

Chromeceptin (94G6) is an IGF signaling pathway inhibitor. Chromeceptin suppresses IGF2 expression at mRNA and protein levels in hepatocyte and HCC cells. Chromeceptin inhibits the phosphorylation levels of AKT and mTOR .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0732
CAS No.: 37905-08-1
Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis [3] .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-16350
CAS No.: 197723-00-5
Synonyms: NKP-1339; IT-139; KP-1339
Research Areas:  

Cancer

BOLD-100 (NKP-1339; IT-139) is the first-in-class ruthenium-based anticancer agent in development against solid cancer with limited side effects. BOLD-100 induces G2/M cell cycle arrest, blockage of DNA synthesis, and induction of apoptosis via the mitochondrial pathway. BOLD-100 has a high tumor targeting potential, strongly binds to serum proteins such as albumin and transferrin and activates in the reductive tumor milieu .
loading...
    loading...
Cat. No.: HY-131183
CAS No.: 2447066-37-5
Purity:  99.52%
Target:  

PROTACs PD-1/PD-L1

Research Areas:  

Inflammation/Immunology

PROTAC PD-1/PD-L1 degrader-1, a PD-1/PD-L1 PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC50 of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner .
loading...
    loading...
Cat. No.: HY-107781
CAS No.: 1782070-22-7
Purity:  98.84%
Research Areas:  

Inflammation/Immunology

PAT-505 is a potent, selective, noncompetitive and orally available autotaxin inhibitor, with an IC50 of 2 nM in Hep3B cells, 9.7 nM in human blood and 62 nM in mouse plasma.
loading...
    loading...
Cat. No.: HY-148049
CAS No.: 1821214-50-9
Purity:  ≥98.0%
TT3 is an ionizable lipid-like material and a lipid nanoparticle (LLNs)-based mRNA delivery vector. TT3 exhibits liver and spleen specificity and excellent delivery efficiency .
loading...
    loading...
Cat. No.: HY-N8439
CAS No.: 1916-59-2
Synonyms: Phx-3
Questiomycin A (Phx-3) is a GRP78 (cytoprotective endoplasmic reticulum chaperone) degrader and enhances the anticancer activity of Sorafenib. Questiomycin A is also an antimicrobial/antibiotic that can be obtained from the metabolite of Pseudomonas chlororaphis HT66. Questiomycin A can be used in research on biological control of cancer and plant diseases .
loading...
    loading...
Cat. No.: HY-N16040
CAS No.: 2936622-30-7
Category:  

Lipids

Target:  

Liposome

DMG-pSar25 is a double lipid-tailed polysarcosine lipid with 25 sarcosine moieties, serving as a PEG lipid substitute in lipid nanoparticle formulations for mRNA delivery. DMG-pSar25 supports mRNA delivery in lipid nanoparticle formulations .
loading...
    loading...
Cat. No.: HY-108868
CAS No.: 492-18-2
Purity:  ≥80.0%
Synonyms: Salirgan; Salurin; Salyrgan
Research Areas:  

Metabolic Disease

Mersalyl (Salirgan) is a potent vascular endothelial growth factor (VEGF) and hypoxia-inducible factor 1 (HIF-1) inducer. Mersalyl induces VEGF and ENO1 mRNA expression. Mersalyl shows diuresis effects [3].
loading...
    loading...
Cat. No.: HY-P990841

Target:  

Glycoprotein VI

Research Areas:  

Cancer

Anti-pan-Glypican Antibody (HS20) is a kind of human IgG1 κ human antibody, targeting to human pan-Glypican. Anti-pan-Glypican Antibody (HS20) can neutralize the heparan sulfate (HS) chains on GPC3 thereby disrupting the Wnt3a-GPC3 interactions leading to blockade of the Wnt3a/β-catenin signaling. Anti-pan-Glypican Antibody (HS20) can be used for the research of cancer, such as hepatocellular carcinoma (HCC) .
loading...
    loading...